945013-20-7

Basic information

• Product Name: 5-chloro-2-(ethoxymethoxy)benzaldehyde
• Synonyms: 5-chloro-2-(ethoxymethoxy)benzaldehyde
• CAS NO: 945013-20-7
• Molecular Weight: 214.649
• Mol File: 945013-20-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-chloro-2-(ethoxymethoxy)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5-chloro-2-(ethoxymethoxy)benzaldehyde(945013-20-7)
• EPA Substance Registry System: 5-chloro-2-(ethoxymethoxy)benzaldehyde(945013-20-7)

Safety Data

• Hazardous Substances Data: 945013-20-7(Hazardous Substances Data)

Upstream product

• 635-93-8 5-chlorosalicyclaldehyde 
• 3188-13-4 ethyl chloromethyl ether 

Downstream Products

• 945013-29-6 C₁₇H₂₁ClO₆ 
• 889854-76-6 [4-chloro-2-({1-[(4-chlorophenyl)sulfonyl]-3,7-dioxo-1,4-diazepan-6-yl}methyl)phenoxy]acetic acid 
• 889854-32-4 tert-butyl [4-chloro-2-((E)-{1-[(4-chlorophenyl)sulfonyl]-3,7-dioxo-1,4-diazepan-6-ylidene}methyl)phenoxy]acetate 
• 889858-30-4 (6E)-6-(5-chloro-2-hydroxybenzylidene)-4-[(4-chlorophenyl)sulfonyl]-1,4-diazepan-2,5-dione 

Relevant articles and documents

Expanding the Reactivity of Donor-Acceptor Cyclopropanes: Synthesis of Benzannulated Five-Membered Heterocycles via Intramolecular Attack of a Pendant Nucleophilic Group

Lewis-acid-induced domino transformations of donor-acceptor cyclopropanes, possessing a nucleophilic center embedded in a donor group, into functionalized 2,3-dihydrobenzo[b]furans and 2,3-dihydrobenzo[b]thiophenes are reported herein. An unusual switch o

7-MEMBERED RING COMPOUND, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF

A 7-membered heterocyclic compound having the formula (I), or its salt, or a solvate thereof with a chymase inhibitory action and useful for the prevention or treatment of various diseases, in which chymase is involved: a method for producing the same, and a pharmaceutical composition useful for the prevention or treatment of diseases, in which chymase is involved, including the compound of having the formula (I), or its pharmaceutically acceptable salt, or a solvate thereof are provided.